Literature DB >> 21047543

Quantifying exploratory low dose compounds in humans with AMS.

Stephen R Dueker1, Le T Vuong, Peter N Lohstroh, Jason A Giacomo, John S Vogel.   

Abstract

Accelerator Mass Spectrometry is an established technology whose essentiality extends beyond simply a better detector for radiolabeled molecules. Attomole sensitivity reduces radioisotope exposures in clinical subjects to the point that no population need be excluded from clinical study. Insights in human physiochemistry are enabled by the quantitative recovery of simplified AMS processes that provide biological concentrations of all labeled metabolites and total compound related material at non-saturating levels. In this paper, we review some of the exploratory applications of AMS (14)C in toxicological, nutritional, and pharmacological research. This body of research addresses the human physiochemistry of important compounds in their own right, but also serves as examples of the analytical methods and clinical practices that are available for studying low dose physiochemistry of candidate therapeutic compounds, helping to broaden the knowledge base of AMS application in pharmaceutical research.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047543      PMCID: PMC3062634          DOI: 10.1016/j.addr.2010.10.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  84 in total

Review 1.  Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.

Authors:  K W Turteltaub; J S Vogel
Journal:  Curr Pharm Des       Date:  2000-07       Impact factor: 3.116

Review 2.  Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.

Authors:  A Shipp; G Lawrence; R Gentry; T McDonald; H Bartow; J Bounds; N Macdonald; H Clewell; B Allen; C Van Landingham
Journal:  Crit Rev Toxicol       Date:  2006 Jul-Aug       Impact factor: 5.635

Review 3.  Accelerator mass spectrometry for biomedical research.

Authors:  Karen Brown; Karen H Dingley; Kenneth W Turteltaub
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 4.  The utility of microdosing over the past 5 years.

Authors:  Graham Lappin; R Colin Garner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

5.  Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine.

Authors:  S D Gilman; S J Gee; B D Hammock; J S Vogel; K Haack; B A Buchholz; S P Freeman; R C Wester; X Hui; H I Maibach
Journal:  Anal Chem       Date:  1998-08-15       Impact factor: 6.986

Review 6.  Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems.

Authors:  K M Wasan
Journal:  Drug Dev Ind Pharm       Date:  2001-04       Impact factor: 3.225

7.  Unlicensed and off label drug use in paediatric wards: prospective study.

Authors:  S Turner; A Longworth; A J Nunn; I Choonara
Journal:  BMJ       Date:  1998-01-31

8.  Human microdosing for the prediction of patient response.

Authors:  Paul T Henderson; Chong-Xian Pan
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

Review 9.  Neuroscience and accelerator mass spectrometry.

Authors:  Magnus Palmblad; Bruce A Buchholz; Darren J Hillegonds; John S Vogel
Journal:  J Mass Spectrom       Date:  2005-02       Impact factor: 1.982

10.  Use of the optogalvanic effect (OGE) for isotope ratio spectrometry of 13CO2 and 14CO2.

Authors:  Daniel E Murnick; Joseph O Okil
Journal:  Isotopes Environ Health Stud       Date:  2005-12       Impact factor: 1.675

View more
  6 in total

1.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

2.  Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Authors:  David W Boulton; Sreeneeranj Kasichayanula; Chi Fung Anther Keung; Mark E Arnold; Lisa J Christopher; Xiaohui Sophia Xu; Frank Lacreta
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 3.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

4.  Quantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy.

Authors:  A Daniel McCartt; Ted J Ognibene; Graham Bench; Kenneth W Turteltaub
Journal:  Anal Chem       Date:  2016-08-09       Impact factor: 6.986

5.  Human in Vivo Pharmacokinetics of [(14)C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing.

Authors:  Erin Madeen; Richard A Corley; Susan Crowell; Kenneth Turteltaub; Ted Ognibene; Mike Malfatti; Tammie J McQuistan; Mary Garrard; Dan Sudakin; David E Williams
Journal:  Chem Res Toxicol       Date:  2014-12-10       Impact factor: 3.739

6.  Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies.

Authors:  Nicole A Kratochwil; Stephen R Dueker; Dieter Muri; Claudia Senn; HyeJin Yoon; Byung-Yong Yu; Gwan-Ho Lee; Feng Dong; Michael B Otteneder
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.